Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.16 +1.98 (+2.00%)
Official Closing Price Updated: 6:30 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
96 97 Next >
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Price Over Earnings Overview: Merck & Co
Via Benzinga
Analyst Ratings for Merck & Co
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
From Amazon.com, Inc.
Via Business Wire
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Announces First-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
Via Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
Although it might seem too conservative, low-volatility stocks should be on your radar to prepare for the unknown. 
Via InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
BMO Capital Markets analyst Evan David Seigerman reiterated an Outperform rating on Merck & Company, Inc. (NYSE: MRK),  
Via Benzinga
Merck to Acquire Caraway Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Three Solid Stocks That Still Have Plenty Of Growth Left
The key ingredient is to find companies with sound fundamentals that aren’t appreciated as they should be. More so if their long-term growth is not fully accounted for. 
Via Talk Markets
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE: 
Via Benzinga
Exposures Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with... 
Via Benzinga
Exposures Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future
The FDA's Pulmonary-Allergy Drugs Advisory Committee  
Via Benzinga
Exposures Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
Exposures Product Safety
2 Healthcare Stocks That Could Make You Richer
Merck and Intuitive Surgical both still have bright futures ahead. 
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
The 3 Best Defensive Stocks for Uncertain Times
These are the best defensive stocks to buy as they represent low beta names and companies with robust fundamentals and cash flows. 
Via InvestorPlace
3 S&P stocks with growth to weather a downturn
S&P 500 components Broadcom, McCormick and Merck stocks are diverse stocks worth tracking for investors seeking strong earnings and dividend growth. 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
There's a lot more at stake than bragging rights. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Qualcomm, Merck And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.